Free Newsletter
Study: Psych drug ads misleading
Ads for psych drugs in medical journals are often misleading, a new study shows. Half the claims made in these ads offered no backup source that could be verified--and of those that were backed up by verifiable citations, almost half the cited studies didn't even support the claims. In some cases, the cited studies directly contradicted the ad's contentions. "When claims are made that aren't supported, the impression created is overly optimistic," lead author Glen Spielmans said.
Curiouser and curiouser, when the researchers asked nine drugmakers about the ads, only three replied, one of them to refuse to supply the sources of data it cited in its own advertising. That company? Wyeth. Ironically, the Effexor XRÂ ad in question is actually headlined "See the data." Now you see it, now you don't.
- check out the study in the Journal of Nervous and Mental Disease
- see the item in Pharmalot
Related Articles:
Studies inflating antidepressant efficacy? Report
To DTC or not to DTC? Report
Does the FDA do enough to regulate drug ads? FDA report
10 reforms for drug advertising. Drug ad report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: